VERONA PHARMA PLC - ADR (VRNA)

Company Profile

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. The company is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The firm's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The firm's wholly owned subsidiary is Verona Pharma, Inc.

Company Info

VERONA PHARMA PLC - ADR

Riverside, 3 More London Place

London SE1 2RE

P: 442032834200

CEO: David Zaccardelli

Employees: 79

Website: https://www.veronapharma.com/